CDNA Earnings Prediction
The chart below shows how CDNA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CDNA sees a -9.37% change in stock price 10 days leading up to the earnings, and a +4.93% change 10 days following the report. On the earnings day itself, the stock moves by +1.59%. This data can give you a slight idea of what to expect for the next quarter's release.
CDNA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
82.88M
23.35%
-10.18%
Gross Margin
66.73%
5.10%
-4.27%
Operating Margin
-12.66%
-70.13%
189.70%
Net Margin
-8.94%
-74.42%
492.05%
EPS
-0.14
-67.44%
366.67%
No Data Available
CDNA Earnings Analysis
CareDx, Inc. Corporation (CDNA.O) Earnings Conference Call
Positive
Third Quarter Revenue Increase: Reported total revenue of $82.9 million for the third quarter, up 23% year-over-year.
Testing Services Volume Growth: Delivered approximately 44,600 test results, up 16% year-over-year, representing the fifth consecutive quarter of sequential Testing Services volume growth.
Testing Services Revenue Increase: Reported Testing Services revenue of $60.8 million, up 27% year-over-year, including $1.2 million associated with tests performed in prior periods.
Cash Generation and Reserves: Generated cash of $12.5 million from operations and ended the quarter with $241 million in cash, cash equivalents, and marketable securities.
EBITDA Improvement Report: Reported adjusted EBITDA gain of $6.9 million compared to an adjusted EBITDA loss of $10.9 million in the same quarter of last year, an improvement of $18 million.
Negative
Quarterly Revenue and Testing Growth: Reported total revenue of $82.9 million for the third quarter, up 23% year-over-year. Delivered approximately 44,600 test results, up 16% year-over-year, and 2% as compared to the last quarter, representing the fifth consecutive quarter of sequential Testing Services volume growth.
Testing Services Revenue Increase: Reported Testing Services revenue of $60.8 million, up 27% year-over-year, including $1.2 million associated with tests performed in prior periods.
EBITDA Improvement Report: Reported a net adjusted EBITDA gain of $6.9 million compared to a $10.9 million loss in the same quarter of last year, an improvement of $18 million.
Gross Margin Improvement: Reported a non-GAAP gross margin for the third quarter was 69%, up 240 basis points as compared to non-GAAP gross margin of 66.6% in the same quarter last year.
Gross Margin Decline: Reported a decrease in Patient and Digital Solutions non-GAAP gross margin for the third quarter was 37% as compared to 39% in the third quarter of 2023.
CDNA FAQs
How does CDNA typically perform around its earnings report dates?
Is CareDx, Inc (CDNA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CDNA Earning Call Sentiment
CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CDNA.O
1.82%Positive
The earnings call reflects strong financial performance with a 23% YoY revenue increase and improved EBITDA. Raised revenue guidance and gross margin expectations, alongside a long-term growth strategy, suggest positive momentum. The Q&A revealed no major concerns, and regulatory issues appear manageable. Despite no shareholder return plan, the overall sentiment is positive, likely resulting in a stock price increase of 2% to 8%.